Sunshine Heart Inc (SSH) 5.26 $SSH
Thoratec Arrests Decline In LVAD Sales In 4th Quarter 2014, Revive-IT Is 'Dead'
Robert Honeywill - Seeking Alpha - Fri Feb 13, 8:36AM CST
This article is a continuation of my series of articles developing an investment strategy based on an area of unmet need in the health sector, viz ., long-term therapies for late stage heart failure. The significant players are Thoratec (NASDAQ:...
SSH: 5.26 (-0.02), THOR: 40.01 (+0.54), HTWR: 88.18 (-0.09)
Sunshine Heart announces inducement grant to Don Villalta under NASDAQ Listing Rule 5635(c)(4)
M2 - Fri Feb 13, 6:36AM CST
Medical device company Sunshine Heart (NasdaqCM:SSH) reported on Thursday that it has awarded Don Villalta an option to purchase 5,000 common stock in connection with his new employment.
SSH: 5.26 (-0.02)
Sunshine Heart Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
GlobeNewswire - Thu Feb 12, 6:07PM CST
Sunshine Heart, Inc. (Nasdaq:SSH), today announced that on February 11, 2015, the Compensation Committee of its Board of Directors, which is composed entirely of independent directors, approved one equity award under Sunshine Heart's New-Hire Equity Incentive Plan, as a material inducement to one individual entering into employment with the Company. The equity award was approved in accordance with NASDAQ Listing Rule 5635(c)(4), which also requires a public announcement of equity awards that are not made under a stockholder approved equity plan.
SSH: 5.26 (-0.02)
If Thoratec's Woes Are Heartware's Gain, That's Disastrous For Both
Robert Honeywill - Seeking Alpha - Wed Feb 04, 8:41AM CST
An area of potential above average real growth This article is a continuation of my series looking at corporations with mechanical heart assist devices as part of a strategy for seeking above average returns by investing in heart health related...
SSH: 5.26 (-0.02), THOR: 40.01 (+0.54), HTWR: 88.18 (-0.09)
Clinical Hold For Revive-IT Trial Raises Questions About Thoratec And Heartware
Robert Honeywill - Seeking Alpha - Wed Feb 04, 8:41AM CST
From the Revive-IT official web-site : REVIVE-IT is a two-part study consisting of a trial and a registry. The purpose of the REVIVE-IT study is to find out whether people with advanced heart failure who are not candidates for a heart transplant...
SSH: 5.26 (-0.02), THOR: 40.01 (+0.54), HTWR: 88.18 (-0.09)
HeartWare: Integral To A Heart Health Related Investment Strategy
Robert Honeywill - Seeking Alpha - Tue Jan 27, 9:53AM CST
An area of potential above average real growth In my article, " Thoratec: At The Heart Of A Health-Related Investment Strategy ", I wrote, Late stage heart failure (NYSE: HF ) is a prime example, with a large and growing population of patients...
SSH: 5.26 (-0.02), THOR: 40.01 (+0.54), HTWR: 88.18 (-0.09)
Johnson & Johnson: No Real Earnings Growth Since 2007; And Don't Ignore Special Items
Robert Honeywill - Seeking Alpha - Fri Jan 23, 11:15AM CST
Special (Abnormal) Items I wrote previously on the subject of "Special Items" in my article, " Johnson & Johnson: When Special Items Are The Norm " Gross and net after tax charges against income for Special Items can be very significant - ...
SSH: 5.26 (-0.02), JNJ: 99.62 (+1.18)
Clouds Still Mar Sunshine Heart's Outlook
Stephen Simpson, CFA - at Seeking Alpha - Fri Jan 16, 10:53AM CST
SSH: 5.26 (-0.02), BSX: 14.98 (+0.24), MDT: 75.26 (+0.33), STJ: 67.48 (+0.65)
Sunshine Heart Provides Corporate Update
GlobeNewswire - Mon Jan 12, 5:35AM CST
Sunshine Heart, Inc. (Nasdaq:SSH) today provided an update on the Company's U.S. Counter HF(TM) and European OPTIONS HF studies along with progress on its next generation, fully implantable C-Pulse Heart Assist System.
SSH: 5.26 (-0.02)
Sunshine Heart's German Erlangen Site Achieves First Implant for OPTIONS HF EU Post-Market Study
GlobeNewswire - Thu Jan 08, 4:30AM CST
Sunshine Heart, Inc. (Nasdaq:SSH) announced today that the Company's German Erlangen site for the OPTIONS-HF study has implanted its first patient with the C-Pulse System for moderate to severe heart failure. Prof. Dr. Michael Weyand of the University Hospital of Erlangen performed the operation, which took place on November 19, 2014. The surgical implantation procedure was successfully completed and the patient suffering from an ischemic cardiomyopathy was discharged from the hospital 8 days post-surgery.
SSH: 5.26 (-0.02)
New finance chief at Sunshine Heart
Seeking Alpha - at Seeking Alpha - Wed Jan 07, 3:50PM CST
SSH: 5.26 (-0.02)
Sunshine Heart Appoints Claudia Drayton as Chief Financial Officer
GlobeNewswire - Mon Jan 05, 4:30AM CST
Sunshine Heart, Inc. (Nasdaq:SSH) announced today the appointment of Claudia Drayton as its Chief Financial Officer. Ms. Drayton, who was formerly Chief Financial Officer and Senior Finance Director for Medtronic Inc.'s Integrated Health Solutions Business, replaces Jeff Mathiesen, who will provide consulting services to the Company through the first half of 2015.
SSH: 5.26 (-0.02)
Sunshine Heart (SSH) Worth Watching: Stock Gains 10.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Dec 23, 8:46AM CST
Sunshine Heart (SSH) was a big mover last session, with shares rising over 10% on the day.
SSH: 5.26 (-0.02), FLDM: 37.93 (-0.47)
Sunshine Heart Provides Update on OPTIONS HF EU Post-Market Study
GlobeNewswire - Mon Dec 01, 4:30AM CST
Sunshine Heart, Inc. (Nasdaq:SSH) announced today that the Company's initial Austrian site for the OPTIONS-HF study has implanted its first patient with the C-Pulse System for moderate to severe heart failure. Prof. Dr. Herwig Antretter of the University of Innsbruck performed the operation, which took place on November 11, 2014. A 92 minute surgical implantation procedure was successfully completed and the patient was discharged from the hospital 7 days post-surgery. This milestone marks the eleventh implantation of the C-Pulse System across fourteen activated EU centers participating in the OPTIONS HF post-market surveillance clinical study.
SSH: 5.26 (-0.02)
Thoratec: At The Heart Of A Health-Related Investment Strategy
Robert Honeywill - at Seeking Alpha - Sun Nov 30, 3:48AM CST
About the headline It is my contention, for Western economies, we will enjoy far lower growth in the future than we have enjoyed over the last several decades. For investors, it is not an optimal strategy to adopt a "rising tide lifts all boats"...
SSH: 5.26 (-0.02), THOR: 40.01 (+0.54), HTWR: 88.18 (-0.09)
Sunshine Heart reveals inducement grants to seven new employees
M2 - Mon Nov 24, 6:35AM CST
The compensation committee of the board of directors of Sunshine Heart (NasdaqCM:SSH), a medical device company, on Friday awarded options to purchase an aggregate of 84,000 shares of its common stock to seven new individuals entering into employment.
SSH: 5.26 (-0.02)
Sunshine Heart Announces Change to Presentation Time at Piper Jaffray 26th Annual Healthcare Conference
GlobeNewswire - Fri Nov 21, 5:31AM CST
Sunshine Heart, Inc. (Nasdaq:SSH) announced today that Dave Rosa, Chief Executive Officer, will be presenting at the Piper Jaffray 26 Annual Healthcare Conference on Wednesday, December 3, 2014 at 10:30 AM EST at The New York Palace Hotel in New York, New York. Mr. Rosa's presentation was originally scheduled for 4:00 PM EST.
SSH: 5.26 (-0.02)
Johnson & Johnson: Growth-Growth-Growth; Win-Win-Win - Part V
Robert Honeywill - Seeking Alpha - Tue Nov 11, 6:00AM CST
In Part IV of this series I provided tables (Cases 1 through 5) illustrating the potentially huge impact of higher or lower PE ratios for an investment in shares of Johnson & Johnson (NYSE: JNJ ). In "Bear" markets, the share prices...
SSH: 5.26 (-0.02), JNJ: 99.62 (+1.18)
Sunshine Heart to Present at Upcoming Investor Conferences
GlobeNewswire - Mon Nov 10, 4:30AM CST
Sunshine Heart, Inc. (Nasdaq:SSH) announced today that the company is scheduled to present a corporate update at the following upcoming investor conferences for the balance of 2014:
SSH: 5.26 (-0.02)
Thoratec Arrests Decline In LVAD Sales In 4th Quarter 2014, Revive-IT Is 'Dead'
Robert Honeywill - Seeking Alpha - Fri Feb 13, 8:36AM CST
This article is a continuation of my series of articles developing an investment strategy based on an area of unmet need in the health sector, viz ., long-term therapies for late stage heart failure. The significant players are Thoratec (NASDAQ:...
SSH: 5.26 (-0.02), THOR: 40.01 (+0.54), HTWR: 88.18 (-0.09)
Sunshine Heart announces inducement grant to Don Villalta under NASDAQ Listing Rule 5635(c)(4)
M2 - Fri Feb 13, 6:36AM CST
Medical device company Sunshine Heart (NasdaqCM:SSH) reported on Thursday that it has awarded Don Villalta an option to purchase 5,000 common stock in connection with his new employment.
SSH: 5.26 (-0.02)
Sunshine Heart Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
GlobeNewswire - Thu Feb 12, 6:07PM CST
Sunshine Heart, Inc. (Nasdaq:SSH), today announced that on February 11, 2015, the Compensation Committee of its Board of Directors, which is composed entirely of independent directors, approved one equity award under Sunshine Heart's New-Hire Equity Incentive Plan, as a material inducement to one individual entering into employment with the Company. The equity award was approved in accordance with NASDAQ Listing Rule 5635(c)(4), which also requires a public announcement of equity awards that are not made under a stockholder approved equity plan.
SSH: 5.26 (-0.02)
If Thoratec's Woes Are Heartware's Gain, That's Disastrous For Both
Robert Honeywill - Seeking Alpha - Wed Feb 04, 8:41AM CST
An area of potential above average real growth This article is a continuation of my series looking at corporations with mechanical heart assist devices as part of a strategy for seeking above average returns by investing in heart health related...
SSH: 5.26 (-0.02), THOR: 40.01 (+0.54), HTWR: 88.18 (-0.09)
Clinical Hold For Revive-IT Trial Raises Questions About Thoratec And Heartware
Robert Honeywill - Seeking Alpha - Wed Feb 04, 8:41AM CST
From the Revive-IT official web-site : REVIVE-IT is a two-part study consisting of a trial and a registry. The purpose of the REVIVE-IT study is to find out whether people with advanced heart failure who are not candidates for a heart transplant...
SSH: 5.26 (-0.02), THOR: 40.01 (+0.54), HTWR: 88.18 (-0.09)
HeartWare: Integral To A Heart Health Related Investment Strategy
Robert Honeywill - Seeking Alpha - Tue Jan 27, 9:53AM CST
An area of potential above average real growth In my article, " Thoratec: At The Heart Of A Health-Related Investment Strategy ", I wrote, Late stage heart failure (NYSE: HF ) is a prime example, with a large and growing population of patients...
SSH: 5.26 (-0.02), THOR: 40.01 (+0.54), HTWR: 88.18 (-0.09)
Johnson & Johnson: No Real Earnings Growth Since 2007; And Don't Ignore Special Items
Robert Honeywill - Seeking Alpha - Fri Jan 23, 11:15AM CST
Special (Abnormal) Items I wrote previously on the subject of "Special Items" in my article, " Johnson & Johnson: When Special Items Are The Norm " Gross and net after tax charges against income for Special Items can be very significant - ...
SSH: 5.26 (-0.02), JNJ: 99.62 (+1.18)
Clouds Still Mar Sunshine Heart's Outlook
Stephen Simpson, CFA - at Seeking Alpha - Fri Jan 16, 10:53AM CST
SSH: 5.26 (-0.02), BSX: 14.98 (+0.24), MDT: 75.26 (+0.33), STJ: 67.48 (+0.65)
Sunshine Heart Provides Corporate Update
GlobeNewswire - Mon Jan 12, 5:35AM CST
Sunshine Heart, Inc. (Nasdaq:SSH) today provided an update on the Company's U.S. Counter HF(TM) and European OPTIONS HF studies along with progress on its next generation, fully implantable C-Pulse Heart Assist System.
SSH: 5.26 (-0.02)
Sunshine Heart's German Erlangen Site Achieves First Implant for OPTIONS HF EU Post-Market Study
GlobeNewswire - Thu Jan 08, 4:30AM CST
Sunshine Heart, Inc. (Nasdaq:SSH) announced today that the Company's German Erlangen site for the OPTIONS-HF study has implanted its first patient with the C-Pulse System for moderate to severe heart failure. Prof. Dr. Michael Weyand of the University Hospital of Erlangen performed the operation, which took place on November 19, 2014. The surgical implantation procedure was successfully completed and the patient suffering from an ischemic cardiomyopathy was discharged from the hospital 8 days post-surgery.
SSH: 5.26 (-0.02)
New finance chief at Sunshine Heart
Seeking Alpha - at Seeking Alpha - Wed Jan 07, 3:50PM CST
SSH: 5.26 (-0.02)
Sunshine Heart Appoints Claudia Drayton as Chief Financial Officer
GlobeNewswire - Mon Jan 05, 4:30AM CST
Sunshine Heart, Inc. (Nasdaq:SSH) announced today the appointment of Claudia Drayton as its Chief Financial Officer. Ms. Drayton, who was formerly Chief Financial Officer and Senior Finance Director for Medtronic Inc.'s Integrated Health Solutions Business, replaces Jeff Mathiesen, who will provide consulting services to the Company through the first half of 2015.
SSH: 5.26 (-0.02)
Sunshine Heart (SSH) Worth Watching: Stock Gains 10.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Dec 23, 8:46AM CST
Sunshine Heart (SSH) was a big mover last session, with shares rising over 10% on the day.
SSH: 5.26 (-0.02), FLDM: 37.93 (-0.47)
Sunshine Heart Provides Update on OPTIONS HF EU Post-Market Study
GlobeNewswire - Mon Dec 01, 4:30AM CST
Sunshine Heart, Inc. (Nasdaq:SSH) announced today that the Company's initial Austrian site for the OPTIONS-HF study has implanted its first patient with the C-Pulse System for moderate to severe heart failure. Prof. Dr. Herwig Antretter of the University of Innsbruck performed the operation, which took place on November 11, 2014. A 92 minute surgical implantation procedure was successfully completed and the patient was discharged from the hospital 7 days post-surgery. This milestone marks the eleventh implantation of the C-Pulse System across fourteen activated EU centers participating in the OPTIONS HF post-market surveillance clinical study.
SSH: 5.26 (-0.02)
Thoratec: At The Heart Of A Health-Related Investment Strategy
Robert Honeywill - at Seeking Alpha - Sun Nov 30, 3:48AM CST
About the headline It is my contention, for Western economies, we will enjoy far lower growth in the future than we have enjoyed over the last several decades. For investors, it is not an optimal strategy to adopt a "rising tide lifts all boats"...
SSH: 5.26 (-0.02), THOR: 40.01 (+0.54), HTWR: 88.18 (-0.09)
Sunshine Heart reveals inducement grants to seven new employees
M2 - Mon Nov 24, 6:35AM CST
The compensation committee of the board of directors of Sunshine Heart (NasdaqCM:SSH), a medical device company, on Friday awarded options to purchase an aggregate of 84,000 shares of its common stock to seven new individuals entering into employment.
SSH: 5.26 (-0.02)
Sunshine Heart Announces Change to Presentation Time at Piper Jaffray 26th Annual Healthcare Conference
GlobeNewswire - Fri Nov 21, 5:31AM CST
Sunshine Heart, Inc. (Nasdaq:SSH) announced today that Dave Rosa, Chief Executive Officer, will be presenting at the Piper Jaffray 26 Annual Healthcare Conference on Wednesday, December 3, 2014 at 10:30 AM EST at The New York Palace Hotel in New York, New York. Mr. Rosa's presentation was originally scheduled for 4:00 PM EST.
SSH: 5.26 (-0.02)
Johnson & Johnson: Growth-Growth-Growth; Win-Win-Win - Part V
Robert Honeywill - Seeking Alpha - Tue Nov 11, 6:00AM CST
In Part IV of this series I provided tables (Cases 1 through 5) illustrating the potentially huge impact of higher or lower PE ratios for an investment in shares of Johnson & Johnson (NYSE: JNJ ). In "Bear" markets, the share prices...
SSH: 5.26 (-0.02), JNJ: 99.62 (+1.18)
Sunshine Heart to Present at Upcoming Investor Conferences
GlobeNewswire - Mon Nov 10, 4:30AM CST
Sunshine Heart, Inc. (Nasdaq:SSH) announced today that the company is scheduled to present a corporate update at the following upcoming investor conferences for the balance of 2014:
SSH: 5.26 (-0.02)
